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ABSTRACT Lymphangioleiomyomatosis (LAM) and pulmonary Langerhans cell histiocytosis (PLCH)
are rare diseases that lead to progressive cystic destruction of the lungs. Despite their distinctive
characteristics, these diseases share several features. Patients affected by LAM or PLCH have similar
radiological cystic patterns, a similar age of onset, and the possibility of extrapulmonary involvement. In
this review, the recent advances in the understanding of the molecular pathogenesis, as well as the current
and most promising biomarkers and therapeutic approaches, are described.
Introduction
Lymphangioleiomyomatosis (LAM) and pulmonary Langerhans cell histiocytosis (PLCH) are rare diseases
characterised by the presence of pulmonary parenchymal cysts (figure 1). Despite their distinctive
characteristics, they both share several features: in addition to the cystic computed tomography (CT) scan
pattern, these two diseases affect young adults more frequently and can show extrapulmonary involvement.
Recent findings have transformed our understanding of these diseases and, as a result, LAM and PLCH are
now classified as neoplastic diseases, according to the recent classification of diffuse cystic lung diseases [1].
Lymphangioleiomyomatosis
What is LAM?
LAM is a rare disease affecting predominantly women of childbearing age. It is characterised by cystic
destruction of the lungs, lymphatic manifestations including lymphangioleiomyomas, and abdominal
tumours known as angiomyolipomas, which usually affect the kidneys [2]. The disease can be sporadic or
associated with the tuberous sclerosis complex (TSC), an autosomal dominant syndrome characterised by
cerebral calcifications, mental retardation, seizures, and hamartomatous lesions in several organs [3, 4].
LAM is caused by mutations in the tuberous sclerosis gene TSC1 and, in most cases, the TSC2 gene, with
consequent loss of function of their protein products hamartin and tuberin, respectively [5–7]. The major
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role of the hamartin/tuberin heterotrimer is inhibition (mediated through the Ras homologue enriched in
brain (Rheb)) of the mammalian/mechanistic target of rapamycin (mTOR), which is an intracellular
kinase that serves as the central regulator of cell growth and proliferation [8–10]. In sporadic or
TSC-associated LAM, inactivating mutations of TSC1 and TSC2 genes result in constitutive activation of
the mTOR pathway.
LAM lesions are characterised by the presence of LAM cells, which include two types of subpopulations:
small spindle-shaped cells expressing smooth muscle-specific proteins, such as α-actin, vimentin and
desmin; and epithelioid-like cells expressing markers of melanoma cells and immature melanocytes, such
as gp100 and MelanA/Mart1 [11, 12]. In fact, LAM has been included in the family of “perivascular
epithelioid cell tumours”, a heterogeneous group of mesenchymal tumours composed of histologically and
immunohistochemically distinctive perivascular epithelioid cells that typically coexpress myogenic and
melanocytic markers [13]. Furthermore, several genetic and cellular findings support the neoplastic nature
of LAM cells. Evidence of loss of heterozygosity (LOH) among TSC genes in lesions of different organs in
patients with LAM is consistent with the tumour suppressor gene model. The TSC mutations that occur in
LAM result in inappropriate and constitutive signalling through the mTOR pathway, which controls
protein translation and is activated in many forms of human cancer [14]. Identical somatic TSC mutations
have been found in the angiomyolipomas and lungs of the same patient, suggesting that LAM cells might
be spread from a common source [5]. In addition, recurrence of LAM in lung transplant recipients and
the presence of LAM cells in the blood and other body fluids are consistent with the metastatic behaviour
of LAM cells [15–18]. More recently, CD44v6, a glycoprotein that binds hyaluronic acid and is associated
with metastatic cancers, has been shown to be expressed on the LAM cell surface [19]. The CD44v6
protein might enable LAM cells to adhere to the extracellular matrix, thus facilitating metastasis.
Although LAM cells exhibit low-grade proliferation and no evidence of cellular atypia, the progressive
infiltration of lung parenchyma, tissue destruction, angiogenesis, lymphangiogenesis, and protease-driven
matrix degradation are additional features that LAM cells have in common with neoplastic cells [20–23].
Biomarkers
Vascular endothelial growth factor-D (VEGF-D) is a lymphangiogenic growth factor that is involved in the
formation of lymphatic vessels and the spread of tumour cells to lymph nodes. A decade ago, levels of
VEGF-D in the serum of patients with sporadic LAM were found to be higher than those detected in
a) b)
c) d)
FIGURE 1 High-resolution chest computed tomography images of a patient with lymphangioleiomyomatosis,
showing round-shaped, thin-walled cysts distributed diffusely throughout the lungs without sparing of lung
bases (a, b), and a patient with pulmonary Langerhans cell histiocytosis with evidence of micronodules and
cystic lesions mainly involving middle and upper lung fields (c, d).
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healthy controls [24]. Subsequently, serum VEGF-D levels in LAM patients were also found to be higher
than those in healthy volunteers and in patients with other cystic or chylous lung diseases, including
PLCH, emphysema and lymphangiomatosis; all of which suggested that such a parameter could be of
value as a diagnostic biomarker [25]. Furthermore, VEGF-D levels were higher in women with TSC and
LAM than in women with TSC showing no evidence of cystic changes on CT scans [25].
A subsequent study on a larger population of LAM patients confirmed that serum VEGF-D levels were
higher in patients with LAM than in healthy subjects [26]. However, when patient samples were grouped,
based on the extent of lymphatic extrapulmonary involvement, the significant difference was maintained
only for LAM patients with lymphatic involvement, and higher VEGF-D levels were associated with a
higher severity score on CT scan analysis and lower decreased lung diffusion capacity (DLCO); suggesting
that serum VEGF-D levels might be a measure of lymphatic involvement in patients with LAM [26].
A prospective study of 48 patients with cystic lung disease of unknown aetiology confirmed the validity of
serum VEGF-D concentration as a diagnostic test. According to the authors’ findings, serum VEGF-D
levels higher than 800 pg·mL−1 could identify LAM with a sensitivity and specificity of 73 and 100%,
respectively [27]. A subsequent study of 75 patients with cystic lung disease reported that serum VEGF-D
levels could identify LAM with a sensitivity and specificity of 87% and 90%, respectively, using
468 pg·mL−1 as the diagnostic threshold [28].
Based on these results, the recent American Thoracic Society/Japanese Respiratory Society (ATS/JRS)
guidelines on the diagnosis and management of LAM recommended VEGF-D testing for non-invasive
diagnostic confirmation of LAM in cases with compatible high-resolution computed tomography (HRCT),
when other confirmatory features previously reported by the European Respiratory Society (ERS)
guidelines (i.e. TSC, angiomyolipomas, chylous pleural effusions or ascites, and cystic
lymphangioleiomyomas) are lacking [29, 30]. The suggested diagnostic threshold is 800 pg·mL−1 (table 1).
The low false positive rate of the test indicates that serum VEGF-D concentrations higher than
800 pg·mL−1 can preclude the need for a lung biopsy in patients with typical HRCT changes. However,
serum VEGF-D testing has a high false-negative rate, meaning that a negative result should not be used to
rule out or exclude LAM disease. Lung biopsy should still be considered in cases when confirmatory
features are lacking. Furthermore, although the 800 pg·mL−1 threshold has subsequently been validated in
different cohorts, problems concerning possible inter-laboratory variability should still be considered [31].
Serum VEGF-D might also be useful as a marker of disease severity and response to therapy. The data
analysis results of a study on the safety and efficacy of sirolimus in LAM: the Multicenter International
Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial, which showed that median serum
VEGF-D levels were reduced in the sirolimus group, but remained stable in the placebo group over the
treatment period [32]. Interestingly, higher VEGF-D levels at baseline were associated with enhanced
improvement in lung function in the sirolimus group and faster lung function decline in the placebo
group.
In a retrospective study, serum VEGF-D levels greater than 800 pg·mL−1 were associated with a faster rate
of decline in forced vital capacity (FVC) and a faster rate of increase in total lung capacity and residual
volume (RV), compared to patients with serum VEGF-D levels less than 800 pg·mL−1 [33].
Matrix metalloproteinases (MMPs) are proteases with a central role in the turnover and degradation of the
extracellular matrix. In the lung, they are involved in tissue remodelling and lymphangiogenesis [34].
TABLE 1 Criteria for a definite diagnosis of lymphangioleiomyomatosis according to guidelines
ERS guidelines 2010 ATS/JRS guidelines 2016
Characteristic HRCT scans# and one of the following:
Tuberous sclerosis complex Tuberous sclerosis complex
Chylous effusions Chylous effusions
Angiomyolipomas Angiomyolipomas
Lymphatic involvement Lymphatic involvement
Serum VEGF-D ⩾800 pg·mL−1
#: numerous (more than 10) thin-walled lung cysts distributed diffusely throughout the lungs without sparing
of lung bases, without any other significant pulmonary involvement (except for multifocal micronodular
pneumocyte hyperplasia in tuberous sclerosis complex). ERS: European Respiratory Society; ATS/JRS:
American Thoracic Society/Japanese Respiratory Society; HRCT: high-resolution computed tomography;
VEGF-D: vascular endothelial growth factor-D.
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MMPs have been implicated in the pathogenesis of LAM: MMPs are present in LAM lesions; MMP
activators have been detected in LAM nodules; and levels of the MMP-3 inhibitor in LAM lesions are
lower than those found in normal lung parenchyma [35–37]. Moreover, serum levels of MMP-9 are higher
in patients with LAM than in normal subjects [38]. More recently, overexpression of MMPs has been
shown in cells lacking TSC1/TSC2 [39]. It can be hypothesised that degradation of the extracellular matrix
by MMPs can facilitate cell migration and contribute to the formation of lung cysts [35].
Monitoring of serum and urinary MMPs could be a useful, though not specific, assessment of disease
severity and response to treatment in patients with LAM [40, 41]. In one patient with severe LAM, urinary
levels of MMP-9 and MMP-2 became undetectable after 3 months of treatment with doxycycline, an
inhibitor of MMPs [42]. Furthermore, an open-label, interventional clinical trial on the efficacy and safety
of doxycycline showed that serum MMP-9 and MMP-2 levels were significantly reduced after 6 months of
treatment [43]. In a randomised, placebo-controlled clinical trial of doxycycline, the urine levels of
MMP-9 were significantly lower in the doxycycline-treated patients than in the placebo group over the
2-year treatment period, whereas no significant difference was found in the serum levels of MMP-2 or
MMP-9 between the two groups over the same period [44].
The TSC LOH is involved in the pathogenesis of LAM; LAM cells, identified by TSC2 LOH, have been
isolated from the blood and other body fluids of LAM patients [17, 18]. Furthermore, detection of the
LOH is reduced after treatment with sirolimus, suggesting that the search for circulating LAM cells in the
blood or other fluids might identify patients at risk of disease progression or spread and/or the response to
potential therapy [45, 46]. Recently, different LOH patterns in different subpopulations of LAM cells, in
various body fluids, have been identified over time in the same patient [47]. These findings suggest that a
single patient might have different clones of LAM cells.
The TSC2 LOH has been recently reported in the blood of patients with other pulmonary diseases,
including sarcoidosis and PLCH, but not in the same populations of cells in which LAM cells are typically
found [48]. However, whether TSC LOH in body fluids could have a clinical role in the management of
LAM has yet to be determined.
Lung function impairment
The most common respiratory symptom of LAM is dyspnoea (over 70% of patients), although pulmonary
function tests (PFTs) can be normal in up to 30% of patients [49, 50]. Airflow obstruction and decreased
lung diffusion capacity (DLCO) are the most frequent functional abnormalities [49–52]. Both airflow
limitation and DLCO correlate with disease severity, assessed by CT scan, LAM histology score and exercise
capacity [13, 53–56]. 25−30% of LAM patients show reversible airflow obstruction [51, 53]. The decline in
forced expiratory volume in 1 s (FEV1) in untreated patients is variable and mostly unpredictable; the
mean annual decline in FEV1 reportedly ranges from 60 to 134 mL per year among different retrospective
studies and clinical trials [12, 44, 57, 58].
LAM patients frequently experience reduced exercise tolerance. Reduced performance during
cardiopulmonary exercise testing (CPET) is common, with decreased maximal workload and oxygen
consumption (V′O2), mainly due to ventilatory and gas exchange abnormalities [51, 59]. Dynamic
hyperinflation (DH) can frequently develop during incremental CPET, and could be associated with the
severity of disease, higher desaturation and increased dyspnoea [60]. In another study of 38 patients,
inhalation of salbutamol caused a slight improvement in FEV1, but did not produce a significant reduction
in DH or dyspnoea during submaximal exercise in comparison to the placebo [61]. Interestingly, a recent
study on physical activity in daily life showed that each of the three parameters of physical activity (steps
per day, physical activity level and minutes of moderate activity) were reduced in LAM patients, compared
to healthy controls. After adjusting for age and long-term oxygen therapy, physical activity level and
minutes of moderate activity were significantly lower in LAM patients, compared to chronic obstructive
pulmonary disease (COPD) patients. These findings suggest a disease-specific impact on daily physical
activity beyond airflow limitations in LAM patients [62].
Therapy
Both sirolimus and everolimus, two mTORC1 inhibitors, target the mTOR activated signalling pathway,
thus inhibiting growth and proliferation of LAM cells [63].
The efficacy of sirolimus in reducing angiomyolipoma volume and increasing functional parameters in
patients with LAM was first demonstrated a decade ago in a pilot study, the Cincinnati Angiomyolipoma
Sirolimus Trial (CAST) [64].
The MILES trial, a randomised placebo-controlled trial on the safety and efficacy of sirolimus in patients
with moderate functional impairment, showed the stabilisation of FEV1 during the 12-month treatment
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period, with frequent, but mostly mild to moderate adverse events (i.e. mucositis, gastrointestinal events,
hypercholesterolaemia, acneiform rash and swelling in the lower extremities) [58]. Improvement in FVC,
quality of life and serum VEGF-D levels were also observed. Discontinuation of therapy caused a more
rapid decline in lung function, similar to that in the placebo group, suggesting the need for continuous
treatment. Sirolimus also improved chylous manifestations of the disease, such as the volume of chylous
effusions and lymphangioleiomyomas [65].
More recently, the effects of sustained treatment with sirolimus have been reported in an observational
study of a cohort of 38 patients with LAM, including patients with lymphatic complications. Treatment
with sirolimus for a period of about 3.5 years stabilised lung function, by slowing the decline in FEV1 and
DLCO, and changes in lung volume occupied by cysts, with an acceptable spectrum of toxicities. The effect
was maintained in a subgroup of 12 patients followed for about 5 years [66].
Another current concern about therapy with mTOR inhibitors is whether low doses of the drug could be
used to maintain therapeutic effects and reduce toxicity. A retrospective study in a small cohort of patients
before and after therapy suggested that sirolimus might be effective in maintaining lung function and
controlling chylous effusions even at a serum trough level less than 5 ng·mL−1 [67]. However, the incidence
of adverse events was similar to that reported in previous studies, except for hypercholesterolaemia.
Prospective studies comparing conventional and low-dose mTOR inhibitor regimens are necessary.
Two randomised controlled trials (EXIST-1 and EXIST-2) showed that everolimus, a second-generation
mTOR1 inhibitor, was effective in reducing the size of giant cell astrocytomas in patients with TSC and
decreasing the size of renal angiomyolipomas in patients with TSC or LAM [68, 69]. An exploratory,
open-label, non-randomised, within-subject dose escalation trial of everolimus in 24 patients with sporadic
or TSC-LAM was subsequently conducted [70]. That study showed that the safety profile of everolimus
was similar to that of sirolimus in the MILES trial. Four serious drug-related adverse events were observed,
including pneumocystis, heart failure, and pneumonia, which were not observed in the MILES study. The
VEGF-D levels decreased throughout the duration of therapy. Treatment with everolimus resulted in
stabilisation of the FVC and improvement in FEV1, relative to baseline. When comparing efficacy results
after 26 weeks of treatment with the data obtained in the placebo-controlled group of the MILES trial, the
improvement in FEV1 observed was slightly greater than the absolute difference seen between sirolimus
and placebo in the MILES study, and the improvement in FVC was smaller than that observed in the
MILES study [70].
Recent ATS/JRS guidelines recommend treatment with sirolimus for patients with abnormal lung function,
defined as an FEV1 less than 70% predicted, or patients with declining lung function. The panel members
for those guidelines also recommend sirolimus for patients with symptomatic chylous fluid effusions
before invasive procedures are considered [29].
To date, hormonal treatments including progesterone, GnRH antagonists, oophorectomy, and
anti-oestrogen therapy with tamoxifen are not recommended, because results of available studies are
controversial or inconclusive, and no controlled clinical trial has been conducted [71–76]. A randomised,
controlled trial comparing the aromatase inhibitor letrozole with a placebo in postmenopausal women
with LAM has been concluded, but the official results are not yet available (NCT01353209).
Doxycycline is a tetracycline antibiotic that inhibits the production and activity of several MMPs; its
potential role in the treatment of LAM was suggested in a report of a patient with severe pulmonary
impairment, in whom the treatment with this drug improved lung function [42]. Two subsequent
open-label, uncontrolled trials showed that the drug led to a reduction in serum and urinary MMPs;
moreover, it was well tolerated in most patients, and was effective in improving FEV1 in a subgroup of
patients with higher baseline FEV1 [43, 77]. However, the follow-up analysis showed that rates of lung
function decline could differ between responders and non-responders, because of the variability in disease
severity at baseline [78]. More recently, a double-blind, placebo-controlled clinical trial of doxycycline
failed to show differences in the mean yearly decline in FEV1 between the placebo and treatment groups.
However, these results should be interpreted with caution, because of the limited number of patients who
completed the 24-month treatmentperiod, due to the high dropout rate [44].
Recurrence of disease-related symptoms and complications after cessation of therapy with mTOR
inhibitors might occur; moreover, patients might not respond to or even be intolerant of the treatment. All
of these findings suggest that mTOR inhibitors are not curative, and have therefore led to a focus on novel
therapeutic strategies. Recent advances in understanding the pathogenesis of LAM suggest new potential
targets.
Autophagy is a critical component of TSC tumorigenesis that is increased by mTOR inhibition, which
probably enhances LAM cell survival and reduces the effects of mTOR inhibitors [79]. The inhibition of
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autophagy in combination with mTOR inhibition has been shown to be more effective than either
treatment alone, in inhibiting survival of TSC2-null cells, the growth of TSC2-null xenograft tumours and
development of spontaneous renal tumours in Tsc2+/− mice [79]. The results of a phase I clinical trial on
the safety and tolerability of sirolimus in combination with hydroxychloroquine in patients with LAM
have been recently published [80]. 13 patients in cohorts of three patients each were treated with sirolimus
and increasing hydroxychloroquine doses (200 and 400 mg daily), and an extension phase at the 400 mg
dose. The treatment period was 24 months, followed by an observation phase off any of the drugs under
study for an additional 24 weeks. Mucositis, headache, and diarrhoea were the most common adverse
events, whereas no serious drug-related adverse events were observed. Analysis of secondary endpoints
showed an improvement in FEV1 and FVC at 24 weeks, both of which remained stable when the higher
dose of hydroxychloroquine was analysed separately. Larger trials are needed to explore the effects on lung
function.
A deficiency of tuberin due to TSC2 mutations results in increased RhoA GTPase activity and cell
survival, an effect that is mediated through mTOR complex 2 signalling. Because of their inhibitory effects
on RhoA GTPase, statins have been considered as a possible therapy in LAM [81]. A retrospective study of
patients who were treated with a combination of sirolimus and simvastatin, or with either sirolimus alone
or simvastatin alone because of hypercholesterolaemia, showed that the combined therapy had no
beneficial effect and did not increase the incidence of adverse events, beyond those expected from the use
of each drug alone [82]. A phase 1–2 clinical trial on combination therapy with simvastatin and mTOR
inhibitors (everolimus and sirolimus) is ongoing (NCT02061397).
The Src kinases, the degradation of which is promoted by autophagy, are key regulators of cellular
proliferation, motility and invasiveness. Thus, decreased autophagy due to mTOR activation in LAM
cells might play a role in the accumulation of active Src in these cells. An increase in active Src has
been found in the lung tissues of patients with LAM and in cultured TSC2−/− cells [83]. Furthermore,
increased Src kinase activation facilitates migration, invasion and inhibition of E-cadherin expression
in TSC2−/− cells by upregulating its transcriptional repressor. A phase 1–2 clinical trial of safety and
efficacy of the inhibitor of Src kinases, saracatinib (SLAM-2), in patients with LAM is underway
(NCT02737202).
The platelet-derived growth factor receptor β (PDGFRβ) is present and active in human and murine TSC
lesions [84]. The safety and efficacy of nintedanib, a small potent inhibitor of the tyrosine kinase FGR
receptor, VEGF receptor, and the platelet-derived growth factor (PDGF) receptor is currently being
investigated in a pilot study of patients with LAM (NCT03062943). The inhibition of tumour angiogenesis
and lymphangiogenesis promoted by PDGF, FGR and VEGF could play a role in preventing the
dissemination of LAM cells and disease progression in LAM.
Pulmonary Langerhans cell histiocytosis
What is PLCH?
Langerhans cell histiocytosis (LCH) is a rare histiocytic disorder of unknown origin that could affect
patients of any age, but is most common in children from 1 to 3 years old.
Different clinical forms of LCH have been categorised into systemic and localised forms. Localised LCH
often affects the bone, skin and lung, and is characterised by a good prognosis with occasional
spontaneous resolution. Systemic LCH affects more than one organ or tissue (e.g. bone, skin,
hypothalamic-pituitary system, lymph nodes, lungs and more rarely, the central nervous system). The
involvement of the so-called “risk organs”, such as the liver, spleen and haematopoietic system, is a
well-established unfavourable prognosticator [85]. The lung could be involved as a single organ, typically
in young smoker adults with equal gender distribution (PLCH), whereas it is less frequently affected in the
systemic form of LCH [86]. The pathogenesis of PLCH is still unclear. Various molecular mechanisms
underlying disease pathogenesis and progression have been found.
The characteristics of PLCH include an accumulation of a large number of CD1a+ cells (Langerhans cells
(LC)) in loosely formed bronchiolocentric granulomas. This results in airspace invasion, cavitation and
consequent destruction of lung parenchyma. Myeloid haematopoietic precursors are recruited from
circulating peripheral blood that further differentiate in the LC of involved tissues. Local growth factors,
such as granulocyte macrophage colony stimulating factor (GM-CSF) and chemokines (CCL20 and
CCL2), have been found around PLCH lesions, and can enhance this differentiation [87, 88]. The presence
of local neoangiogenesis in association with the action of cell adhesion molecules could contribute to the
accumulation of LC, T lymphocytes and inflammatory cells [89]. A peculiar characteristic of PLCH
granulomas is their ability to destroy and remodel the surrounding lung parenchyma [90]. The mechanism
is still unclear, but CD1a+ cells found in the granulomas show a different phenotype, compared to the
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same cells grown under physiological conditions in vitro. In fact, different types of markers of membrane
maturation have been detected in LC granulomas. These markers are similar to those usually found on the
surface of dendritic cells after exposure to various pathogens [91]. However, the CD1a+ cell-mediated
cytotoxic action of T lymphocytes seems to be impaired, and for this reason, CD1a+ cells are unlikely to
be the only cause of tissue destruction. Several metalloproteinases that have been found in LCH
granulomas might also be involved in parenchymal damage [92]. Moreover, interleukin-17 might be
involved in tissue remodelling [93]. In addition, activation of Notch1 signalling pathways seems to be
responsible for the peculiar phenotype of LCH cells [94].
Whether PLCH is a reactive or clonal/neoplastic disease is still an important question that pertains to the
pathogenesis of PLCH. The hypothesis of a reactive response to an unknown agent is supported by the
large number of inflammatory/immune cells found in PLCH granulomas, and by the absence of
pathological features like mitotic figures, or frequent spontaneous resolution after smoking cessation [95].
Furthermore, one study that analysed CD1a+ cells from lung biopsies of PLCH patients revealed the
polyclonal nature of these cells [96]. Another study conducted on LC derived from extrapulmonary lesions
of focal or systemic forms of LCH reported a clonal nature of these cells [97]. Therefore, the issue remains
a controversial one.
The recent findings of a proto-oncogene mutation (BRAFV600E) in 38% to 69% of the LC in systemic LCH
granulomas [98–101], in 28% of patients with PLCH [86], and in 54% to 82% of patients with Erdheim–
Chester Disease (ECD) [102, 103], supports the neoplastic theory. In fact, the BRAFV600E mutation has
been found in different tumours, such as malignant melanomas and in almost all cases of hairy cell
leukaemia [104].
The BRAFV600E mutation determines the constitutive activation of the mitogen activated protein kinase
(MAPK) pathway, thus deregulating the control system of cell differentiation and survival. Interestingly,
MAPK pathway-independent activation in LCH granulomas has been found, even in the absence of
BRAFV600E mutations, suggesting a key role of MAPK in LCH pathogenesis [105, 106].
The simultaneous presence of NRASQ61K/R and BRAFV600E mutations carried by different cell clones has
been demonstrated in several PLCH lesions [107]. Moreover, NRASQ61 has been found in lung lesions, but
not in systemic LCH lesions. In one patient, the NRAS mutation occurred in pulmonary lesions, but not
in skin lesions.
The role of genetic mutations in LCH and PLCH is still not fully understood. Patients with the BRAFV600E
mutation in LC were generally younger compared to non-carrier BRAFV600E patients; however, no link was
observed with the phenotype. Furthermore, the mutation increased the risk of recurrence of the disease,
without any changes in survival [108]. In addition, children with the BRAFV600E mutation show increased
resistance to first-line treatment [109]. Further studies are needed to determine whether the involvement
of BRAF and MAPK pathways could be useful for the stratification of patients affected by PLCH and
identification of specific outcomes.
A large amount of evidence confirms the key role of smoking in the pathogenesis of PLCH. The rarity of
the disease compared to smoking rates in the general population suggest a predisposition in patients
affected by the disease. The pathogenic mechanism by which smoking could induce the disease remains
unclear. Smoking induces changes in the epithelium of distal bronchioles and an accumulation of CD1a+
cells in healthy smokers, different lung diseases and in murine models [107]. Furthermore, it stimulates
the production of local cytokines involved in the proliferation, differentiation and activation of dendritic
cells in PLCH lesions [110–112].
Osteopontin, a glycoprotein, the secretion of which is increased by nicotine, was increased in the
bronchoalveolar lavage (BAL) fluid of smoking patients with PLCH, compared to that of healthy smokers.
Osteopontin has a chemoactive effect on monocytes/macrophages and dendritic cells; moreover, its
overexpression in murine models creates PLCH-like lesions [113].
Biomarkers
PLCH is a disease with a very typical radiological pattern, which may be diagnostic if clinically consistent.
However, some useful biomarkers could improve the diagnostic process, particularly in the presence of
atypical manifestations. BAL can be useful in the diagnosis of PLCH [114]. Differential cell counts in
PLCH patients might reveal an increase in eosinophils and neutrophils compared to healthy smokers, with
a normal percentage of lymphocytes [115]. Elevated numbers of CD1a+ BAL cells have been found in
PLCH and, interestingly, the number of these cells is not influenced by smoking habits; thus, any number
of CD1a+ BAL cells greater than 5% of the total number of cells is considered a biological marker of
PLCH [116].
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The CD207 (an antibody against langerin) is another useful LC marker. The quantity of this protein in the
BAL fluid of PLCH patients is significantly increased compared to that of patients with sarcoidosis and
idiopathic pulmonary fibrosis [117].
Transbronchial lung biopsies have shown poor sensitivity for the diagnosis of PLCH, because of the
patchy nature of the disease with a focal distribution, and the small amount of tissue that can be obtained
with this procedure [118]. Instead, with the use of cryobiopsy, larger samples can be obtained, thereby
increasing the diagnostic yield [119]. Unfortunately, these procedures can all be complicated by
pneumothorax; thus, surgical lung biopsy seems to be a safer procedure to obtain tissue samples.
Techniques of immunohistochemistry using monoclonal antibodies against CD1a and langerin (CD207)
facilitate the detection of LC in lung biopsies. In contrast, detection of cytoplasmic protein S100 is not a
specific assay.
The BRAFV600E mutation, as previously mentioned, is frequently associated with LCH, ECD and in some
cases, PLCH. Immunohistochemical detection of its expression is an effective method, following bioptic
tissue confirmation, for screening patients who could benefit from specific treatment. However, it could be
very difficult to detect mutations in tissue biopsies from histiocytosic patients. It is for this reason that a
droplet-digital PCR assay for quantitative detection of BRAFV600E mutation in plasma and urine cell-free
DNA has been recently performed in patients with ECD or LCH. The procedure provided a reliable method
to detect the mutation and monitor the response to specific treatments with RAF inhibitors [120, 121].
Fluorodeoxyglucose-positron emission tomography (FDG-PET) scan can play a role as a radiological
biomarker. Fluorodeoxyglucose is absorbed and metabolised by LC, thereby enhancing the identification of
histiocytic lesions in different organs. Although this technique is neither sensitive nor specific for
pulmonary lesions, it is particularly useful in detecting multisystem involvement of LCH and assessing
skeletal involvement [122].
Lung function impairment
Patients affected by PLCH frequently show a reduction in DLCO [86]. An obstructive respiratory pattern on
PFTs has been observed in up to 50% of patients, whereas a restrictive pattern has been described in a
small number of patients [123]. Severity of airflow limitation is significantly related to the parenchymal
extension of the disease [124].
Daily activities are largely limited in PLCH patients. Decreased maximum oxygen consumption (V′O2
peak) and reduced 6-min walking distance have both been demonstrated. A correlation between V′O2 peak
and resting dead space/tidal volume ratio (VD/VT), RV and resting alveolar-to-arterial oxygen tension
difference, and DLCO have also been observed [125]. Recently, ROLLAND-DEBORD et al. [126] collected data
on dyspnoea, PFT and CPET in 62 patients. 44 subjects (71%) showed exercise limitation (V′O2 peak
<84%). No difference was found in dyspnoea score between patients with impaired and normal aerobic
capacity. Despite possible biases related to the retrospective design of the study, multidimensional analysis
TABLE 2 Distinctive features of lymphangioleiomyomatosis (LAM) and pulmonary Langerhans
cell histiocytosis (PLCH)
LAM PLCH
Related to smoking Not evident Strong
Gender predilection Yes (female) No
Genetic mutations TSC1 or more frequently,
TSC2
BRAFV600E, NRAS, MAP2K1
HRCT pattern Cystic Nodular-cystic
Cystic
Nodular
Multisystem involvement Frequent Possible
Treatment Sirolimus# Smoking cessation
Steroids
Vinblastine
Possible role of cladribrine and BRAF
inhibitors
#: approved by the US Food and Drug Administration in 2015, recognised as orphan drug by the European
Medicines Agency in 2016. HRCT: high-resolution computed tomography.
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showed that the reduction of aerobic exercise capacity in patients with PLCH has a multifactorial origin,
which includes gas exchange, air trapping, ventilatory abnormalities and hyperpnoea [126].
Therapy
The first therapeutic approach recommended for patients affected by PLCH is smoking cessation [127, 128].
Smoking cessation for at least 6 months is associated with reduced longitudinal decline in lung function
[125]. The efficacy of this approach on extrapulmonary manifestations is not yet well defined. Although
smoking cessation is the only treatment required for most patients, oral corticosteroids are also frequently
prescribed for patients with progressive functional deterioration, despite smoking cessation. Unfortunately,
strong evidence of the efficacy of this treatment in this population is still lacking, because all studies have
been retrospective and have not taken the effects of smoking cessation into consideration [129].
Some case series have reported the results obtained with the use of chemotherapies such as vinblastine,
methotrexate, cyclophosphamide and etoposide in patients with progressive disease that is non-responsive
to steroids, or with multiorgan involvement [130–132]; no clear improvement in the patients’ condition
was observed. For this reason, these treatments should be reserved as rescue therapies in a limited number
of non-responding patients. Cladribine (2-chlorodeoxyadenosine) is a drug with cytotoxic effects on
lymphocytes and monocytes. It has been shown to be effective in some patients with progressive PLCH,
and in a small number of adult patients with a multisystem or aggressive multifocal form of LCH, when
used alone or in combination with corticosteroids [133]. Furthermore, in a retrospective study conducted
on a small number of patients, cladribine was found to improve respiratory function and reduce the size of
cysts, even in patients with advanced disease [134, 135]. A clinical phase II open-label trial on the efficacy
of cladribine in PLCH patients with functional pulmonary deterioration is ongoing (NCT01473797).
Findings of the presence of the BRAFV600E mutation in LCH, ECD and PLCH have raised the possibility
of targeted therapies in selected patients. Vemurafenib, an inhibitor of mutant BRAF that is used in the
treatment of BRAFV600E-associated hairy cell leukaemia [136], has been successfully used in three patients
with multisystemic and refractory ECD, leading to a rapid clinical and biologic improvement, just 1 month
after treatment. Furthermore, vemurafenib administered to eight patients with BRAFV600E
mutation-multisystemic ECD, which was refractory to first-line treatment, resulted in an improvement of
general symptoms and a persistent response, with a median follow-up time of 10.5 months (range
6–16 months). Adverse effects on the skin were frequent and severe [137]. Recently, 18 BRAFV600E
mutation-positive ECD/LCH patients were treated with a BRAF inhibitor, resulting in stabilisation of the
disease in the majority of cases. Interestingly, no disease progression has been reported during this form of
treatment [138].
Conclusions
The conditions LAM and PLCH are the most common pulmonary cystic diseases. They both differ in
their pathogenic mechanisms, neither of which are yet fully understood. Currently, both diseases seem to
act as neoplastic disorders with extrapulmonary involvement. In particular, the extrapulmonary
involvement might occur more frequently in LAM patients (table 2). Findings on the pathogen-associated
molecular patterns of the diseases raise possibilities of the use of new therapeutic strategies. However, the
results of ongoing studies, which hopefully will only be the start of further clinical investigations, will aid
in establishing better comprehension of the possible role of novel therapeutic options. Targeting multiple
signalling pathways might be a strategy for managing LAM, whereas cladribine and BRAF inhibitors are
presently the most promising treatments for aggressive PLCH.
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